IPOs: NeuroSigma withdraws, NovoCure and SynCardia to go out; Ubl to leave AdvaMed;

@FierceMedDev: ICYMI: In latest biopharma-med tech pairing, Teva snaps up respiratory compliance tracker Gecko. More | Follow @FierceMedDev

@StacyALawrence: JDRF, ADA redefine Type 1 diabetes framework to encourage early diagnosis, prevention. Story | Follow @StacyALawrence

@VarunSaxena2: From @FierceMedDev's special report on recalls: Patients struggle to safely use HeartWare's blood pump. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Shire chalks up victory in Vyvanse patent battle. Article | Follow @EmilyWFierce

> Epilepsy device maker NeuroSigma has withdrawn its $50 million IPO, just as brain cancer device player NovoCure seeks $344 million and total artificial heart player SynCardia Systems aims for $28 million in IPOs slated for this week. More

> AdvaMed President and CEO Stephen Ubl is resigning as of Oct. 15; the group is searching for a replacement. He was rumored last week to be joining biopharma industry association PhRMA. More

> Lima has acquired the Japanese rights to the Zimmer Unicompartmental High Flex Knee and the Discovery Elbow System; it had acquired European rights to these earlier this year as part of Zimmer's effort to appease regulators for its combination with Biomet. More

> Thoratec ($THOR) has reported positive 6-month results in its HeartMate 3 CE mark trial for its LVAD circulatory device to support and restore failing hearts. More

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novo scores a game-changing diabetes approval, reversing an embarrassing rejection. Article | Follow @JohnCFierce

@DamianFierce: Here's what it's like to try to get Sovaldi in my home town. More from The Atlantic | Follow @DamianFierce

> Roche scores an MS first with a potential blockbuster on its hands. Story

> Roche wins kudos for game-changing atezolizumab cancer data. More

> Westphal's Verastem concedes lead drug flopped in PhII mesothelioma study. Article

Pharma News

@FiercePharma: AKC-funded study IDs similar lymphoma gene types in dogs and people. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sun Pharma unit Mutual Pharma recalls 216,766 bottles that may have chemical leaching labels. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Roche is 'well placed' for U.S. pricing tussle, CEO says. Report | Follow @CarlyHFierce

> Novo combats talk of insulin price war with 'moderate premium' on brand-new Tresiba. Story

> How much more does the U.S. pay for drugs? Up to 10 times more, report says. Article

Animal Health News

> USDA unveils plan to battle avian flu if it re-emerges this fall. Story

> Sanofi rumored to be weighing Merial spinoff. Report

> Investors trounce Aratana on dashed hopes for canine lymphoma drugs. More

> AKC-funded study IDs similar lymphoma gene types in dogs and people. Story

> Rhizen moves into midstage trial of pill to treat canine lymphoma. Article

Biotech IT News

> BioClinica buys pharmacovigilance outfit to continue evolution. Article

> AstraZeneca opens data vault for cancer combo efficacy prediction challenge. Report

> Feds prioritize researcher access to health data in IT action plan. More

> Bayer pairs Genedata Profiler and iRODS to manage omics data analysis. Story

> Venter's HLI strikes low-cost exome sequencing deal to swell data repository. Article

Pharma Marketing News

> International payer report shows U.S. prices almost 10X higher for some meds. Item

> Novartis backs DC Comics graphic novel starring rare-disease hero and his canine sidekick. More

> NEJM: FDA's proposed risk-disclosure guidelines still aren't enough. Story

> Don't be quick to peg Merck's Keytruda in second place for NSCLC, analyst says. Article

> Not so fast, Hillary. Ad industry will fight with pharma against DTC tax moves. More